Called $GOOGL bullish on Sep 11, 2025: $GOOGL rose 41% in 5 months.
View call →When AI makes intelligence cheap, who stands to benefit?
Cite asCryptoQuant has tracked the directional calls on ADBE by @reboundcapital on Substack since Jun 2025: not yet scored on ADBE (as of Nov 19, 2026).
Other assets covered (11)
2 ADBE calls on record, a thin history.
Relative view by default: fewer than 30 ADBE calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @substack:reboundcapital to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
Top Rebound Stocks for Nov’26
The markets dropped sharply after the election results and have largely recovered. We may see another round of selling as the Middle East war, the questions over Nvidia’s CEO, and the debate over AI capex in 2027 play out. This may give us another sharp drawdown in the near term. This is how every drawdown will be talked about if the market falls. First, the stock will fall. Then people will come up with a litany of reasons to explain the drop, and the online discourse will become mostly negative. One of these explanations will become the dominant narrative, and the derating can continue for weeks to many years. It may be warranted ( the market is usually right ), but sometimes the market gets it wrong and gives us an opportunity. Buying into these sharp drawdowns is how the Rebound Portfolio has beaten the S&P 500 by 8 percentage points over the past year. RC portfolio Performance | As of 11th Nov 2026 Now let’s discuss a few interesting ideas on our radar. Below, we present 5 potential rebounds. For each name, we cover why the stock is down, our take ( where we would get interested/consider buying, if at all ), and the KPIs we will track. Welcome to Rebound Capital. We study beaten-down stocks and businesses that have made successful comebacks. Subscribe for free to join our growing community of 28,800+ subscribers and make sure you don’t miss our next briefing. Subscribe now TEXAS PACIFIC LAND ($TPL) Texas Pacific Land is one of the largest landowners in Texas. They own ~870k acres of land in West Texas. Most of this land is in the Permian Basin, which is the USA’s busiest oil field. The business model is to lease its land to oil drilling companies and take a royalty on each barrel, as well as for other activities on its land, such as pipelines. Its total revenue was $798M in 2025, reported in 2 segments: Land ( $491M ) and Water ( $308M ). Its key business segments are: Oil and gas royalties ( $412M, about half of revenue ) Water sales ( $170M ) to fracking companies Water royalties ( $124M ): fee on the salty wastewater that comes up with the oil Easements and other ( $92M ). Rent from data centers being set up on its land would be a fifth revenue stream and is close to 0 today. The business is highly profitable and converts 60% of revenue to net profit. It needs almost no capital, so $498M ( ~62% of revenue ) became free cash flow in 2025. It has no debt. Moat The moat is the large land bank it owns in the Permian Basin. Nobody is building another large land bank like this in such a strategic area. Anyone who wants to drill, lay a pipe, or move water across it has to pay. The land bank is now valuable for data center construction, though that hasn’t materialized in 2-3 years of AI expansion. What Went Wrong TPL is down ~50%. The stock peaked at ~$547 in February. It now trades at ~$275. The drawdown is primarily due to TPL’s high starting valuations and high expectations for a material data center to be built on TPL’s land. Investors were too bullish on data center prospects: In December 2025, TPL invested $50M in Bolt, a data center developer chaired by former Google CEO Eric Schmidt. After this news, TPL’s stock rose ~80% in 2 months. This optimism has not translated into business results, though, as no material data center deals have been announced. Texas paused data center permits: In September, the outgoing governor told regulators to stop issuing data center permits until audits of the grid and water supply are done. A new governor takes office in January, and TPL’s management expects a similar approach. This is a live risk to the whole DC thesis in TPL. Doubts about the AI buildout: The market has become much more selective regarding the AI buildout. The market is demanding a certain ROI and waiting for projects to receive funding before assigning a multiple to expected AI revenue. Our Take This is an amazing royalty business model, with a valuation floor due to the large land bank ( though much lower than today’s price ). Our issue with the stock is its trading price. At ~$275, TPL is a ~$19B company trading at ~30x free cash flow. For a royalty business tied to oil, this is a very high multiple and reflects strong growth from data center projects on TPL’s land. A key risk is that the DC projects may not be as lucrative as the market expects. LandBridge, a peer, expects $10M-$20M a year for each GW of data centers on its land. Our base case assumes 3 to 5 GW gets built on TPL’s land by 2031. That would bring in ~$30M-$100M a year. Even the top of that range is small next to the ~$620M of free cash flow TPL makes today. Potential Buy levels and KPIs we are tracking We estimate the stock’s base value is ~$190 per share. We would get interested below ~$170. The most important KPI for this thesis is revenue outside oil and gas royalties ( water, easements, and data centers ). It grew 13% in Q3, with the revenue from data centers at 0. The current valuation already assumes a major data center deal. BOSTON SCIENTIFIC ($BSX) Boston Scientific is one of the world’s largest medical device companies. It is best known for its cardiovascular health products. The company has a deep moat. Doctors train for years on one company’s devices and rarely switch, and every new device needs years of clinical trials before it can be sold. Revenue was $20.1B in 2025 ( +20% YoY ), and ~64% of it came from the US. Cardiovascular is about two-thirds of revenue ( $13.3B ). Two products have driven the stock over the last 3 years. Watchman is an implant that lowers the risk of stroke in patients with an irregular heartbeat. Farapulse treats that irregular heartbeat with electrical pulses in place of heat or cold. Recently, growth in both of these growth drivers has collapsed, and in the most recent Q3 earnings, revenue was $5.14B, up just 1.5% YoY. The stock has lost its premium valuation primarily due to weaker growth. What Went Wrong The stock peaked at ~$108 in Sep’25 and now trades at ~$45, a ~59% drawdown. That is ~14x this year’s guided earnings. Three guidance cuts in one year: management has repeatedly ( 3 times ) cut its full-year revenue guidance. Originally, in February, management guided to 10.5%-11.5% sales growth for 2026. Recently, it has now guided for ~4.25% revenue growth for 2026. The EPS guidance has come down as well. Segments driving the last 2-3 years of growth are now shrinking: Watchman and electrophysiology products drove much of Boston’s growth. In the latest quarter, Watchman sales fell 6% YoY, and electrophysiology sales fell 5%. This is driven by increasing competition in these products and the consequent market share loss for Boston. It is very difficult to predict when this share loss can be stemmed. Weak 2027 commentary: Management has called 2027 the ‘trough year’. This implies another weak year for Boston. Given this commentary, the market will not re-rate the stock. Cyberattack in August: The breach cost $150M in revenue in Q3 and will also hit Q4 results. This is a temporary blip for us, but it did lead to poor sentiment regarding the company. Penumbra deal: Boston is taking on ~$11B of new debt to buy Penumbra for $14.5B. The deal closes in early 2027. Our Take The company has been losing share in its 2 blockbuster products, and it has no revenue-floor guidance for them. Until these products stabilize, the market will not re-rate the stock, and we will monitor the business results until then. The rest of the business is doing relatively well, and the company will be back on the growth path once the shrinking businesses stabilize. The next version of Farapulse is due in early 2028. Potential Buy levels and what we will track We will wait. We value Boston at ~$40 a share, about today’s price. The number we track is US electrophysiology sales growth, and it needs to stop falling before we would buy. The next date is the Q4 results and the 2027 guidance in early February. Next up, we present our research on Tyler Technologies, Deckers, and Marvell. Read more
View original →Earnings Review: AMD, MELI, TIC, XPEL, ZTS
DC revenue up 97% and 80%+ 2027 growth guide put AMD toward $100B revenue
View original →November 2026 Portfolio Update
Amazon is our largest holding; AWS at 39% growth and we're early in the AI build-out.
View original →Earnings Review: $AMZN and $LLY
GLP-1 volume +53% beats a 15% price decline. Retatrutide filing in Q1'27 is the next catalyst.
View original →Earnings Review: GOOG, MSFT, KLAC, LRCX
MSFT enables enterprise AI adoption, FCF positive, though the easy re-rating is behind us
View original →